Human Chromogranin A ELISA Kit

Comparison of available chromogranin A assays

Background

This ELISA is designed, developed and produced for the quantitative measurement of human chromogranin A in EDTA-plasma or serum sample. The assay utilizes the two-site “sandwich” technique with two selected antibodies that bind to different epitopes of human chromogranin A. Assay calibrators, controls and patient samples are added directly to wells of microplate that is coated with a polyclonal chromogranin A antibody. After the first incubation period, the antibody on the wall of microtiter well captures human chromogranin A in the sample and unbound protein in each microtiter well is washed away. Then a horseradish peroxidase (HRP)-labeled monoclonal anti-human chromogranin A antibody is added to each microtiter well and a “sandwich” of “monoclonal antibody – human chromogranin A – polyclonal antibody” is formed. The unbound monoclonal antibody is removed in the subsequent washing step. For the detection of this immunocomplex, the well is incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to the chromogranin A on the wall of the microtiter well is directly proportional to the amount of chromogranin A in the sample. A calibration curve is generated by plotting the absorbance versus the respective human chromogranin A concentration for each calibrator on point-to-point or cubical scales or 4 parameter curve fits. The concentration of human chromogranin A in test sample is determined directly from this calibration curve.

Product Summary

​​​​​​​Chromogranin A is a 49 kDa acidic protein that consists of 439 amino acids encoded on chromosome 14. Chromogranin A has been identified in a number of normal and neopastic endocrine tissues. It is demonstrated that an elevated level of circulating chromogranin A is a marker for tumors of neuroendocrine origin. However, the most significant clinical use of chromogranin A is related to the diagnostic procedure in patients with pheochromocytoma. The following is a short summary of the potential usages of chromogranin A.
1. A very sensitive (83%) and highly specific (96%) marker in the evaluation of actual or suspected pheochromocytoma. Drugs commonly employed in the diagnosis or treatment of pheochromocytoma have little effect on the plasma chromogranin A level, which is a great advantage of measuring chromogranin A over catecholamines.
2. To ascertain the source of a tumor. A high chromogranin A level indicates that the tumor arises from neuroendocrine tissues.
3. Endocrine tumors that do not produce their specific hormones, for example, calcitonin negative but chromogranin A positive, C-cell carcinoma; zero-cell carcinoma; beta-cell carcinoma; parathyroid carcinoma.

For in-vitro diagnostic use.